Cronos Group Inc. Common Share (CRON)
Stock · NASDAQ · Health Care
$3.21as of 10/16/2026
Price chart
Active signals
CRON Signal Track Record
How signals performed across all stocks →What CRON's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | -1.2% | 43% | September 30, 2026 |
| Bollinger Band Breakout | 24 | -4.3% | 17% | July 30, 2026 |
| 200-Day Moving Average TouchActive now | 17 | +2.6% | 53% | June 15, 2026 |
| Bollinger Band Breakdown | 13 | +6.9% | 77% | March 20, 2026 |
| Any 20-session window (baseline) | -0.4% | 47% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About CRON
Cronos Group Inc., a cannabinoid company, engages in the cultivation, production, distribution, and marketing of cannabis products in Canada, Israel, and internationally. It offers dried flowers, pre-rolls, oils, vaporizers, edibles, and tinctures under the Spinach, Lord Jones, Lit, and Peace Naturals brand names. The company is headquartered in Stayner, Canada.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Employees
- 610
- Website
- thecronosgroup.com/
Fundamentals
- 1-day range
- $3.19$3.28
- Market cap
- $1.16B
- P/E (trailing)
- 16.88
- P/E (forward)
- -80.63
- EPS (trailing)
- $0.18
- Dividend yield
- —
- Beta
- 1.21
- Avg. volume
- 1.13M
How Cronos Group Inc. Common Share Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
1 analyst ratings
Cronos Group Inc. Common Share Competitors
Chosen by industry and closest market cap.
- CRONCronos Group Inc. Common Share$3.21▲ 0.31%Market cap $1.16BP/E 16.88$3.23$4.99
- GLASGlass House Brands Inc. Subordinate Voting Shares$3.19▼ 14.02%Market cap $760.64MP/E —$4.2$14
- TRLVTrulieve Cannabis Corp. Subordinate Voting Shares$10.01▼ 2.82%Market cap $1.73BP/E —$7.82$12.93
- TLRYTilray Brands Inc. Common Stock$3.04▼ 5.30%Market cap $517.36MP/E —$3.07$18.4
- CGCCanopy Growth Corporation Common Shares$0.713▼ 3.13%Market cap $400.49MP/E —$1.05$3.28
- SNDLSNDL Inc. Common Shares$1.25▲ 3.31%Market cap $312.36MP/E —$1.13$2.57
- USNAUSANA Health Sciences Inc. Common Stock$15.54▲ 1.04%Market cap $274.91MP/E 32.28$12.57$23.59
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| CRON Cronos Group Inc. Common Share | $1.16B | 16.88 | $3.21 | ▲ 0.31% | $3.23$4.99 |
| GLAS Glass House Brands Inc. Subordinate Voting Shares | $760.64M | — | $3.19 | ▼ 14.02% | $4.2$14 |
| TRLV Trulieve Cannabis Corp. Subordinate Voting Shares | $1.73B | — | $10.01 | ▼ 2.82% | $7.82$12.93 |
| TLRY Tilray Brands Inc. Common Stock | $517.36M | — | $3.04 | ▼ 5.30% | $3.07$18.4 |
| CGC Canopy Growth Corporation Common Shares | $400.49M | — | $0.713 | ▼ 3.13% | $1.05$3.28 |
| SNDL SNDL Inc. Common Shares | $312.36M | — | $1.25 | ▲ 3.31% | $1.13$2.57 |
| USNA USANA Health Sciences Inc. Common Stock | $274.91M | 32.28 | $15.54 | ▲ 1.04% | $12.57$23.59 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- 'DEA Judge Pauses Marijuana Rescheduling Hearing As Opponents Highlight Government Report Detailing ‘Gaps’ In Federal Processes'- Marijuana MomentBenzinga · 9/29/2026
- Can Cronos turn production and brand power into a bigger cannabis comeback?Yahoo · 9/28/2026
- Canadian Penny Stocks To Watch In September 2026Yahoo · 9/28/2026
- Cronos Group Inc. (CRON:CA) Analyst/Investor Day TranscriptSeekingAlpha · 9/25/2026
- Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global AmbitionsYahoo · 9/24/2026
- Cronos Group Inc. (CRON:CA) Analyst/Investor Day - SlideshowSeekingAlpha · 9/24/2026
- Cronos Hosts 2026 Investor DayYahoo · 9/24/2026
- Labaton Keller Sucharow LLP Announces a Proposed Settlement in the Cronos U.S. Securities SettlementYahoo · 9/23/2026
Insider Activity
Insider Actions →- RUDYK JAMES DANIEL · August 6, 2026 · Grant48.9K
- ADLER JASON MARC · August 6, 2026 · Grant48.9K
- Garnick Murray R · August 6, 2026 · Grant48.9K
- Jared Matthew Kenost · May 12, 2026 · Option Exercise9.4K
- Jared Matthew Kenost · May 12, 2026 · Grant30.0K
- Jared Matthew Kenost · May 12, 2026 · Tax Withholding3.7K @ $2.75
- Adam Wagner · May 12, 2026 · Option Exercise10.4K
- Terrence Gregory Joseph Doucet · May 12, 2026 · Option Exercise10.6K
- Terrence Gregory Joseph Doucet · May 12, 2026 · Tax Withholding5.2K @ $3.75
- Shannon Buggy · May 12, 2026 · Option Exercise20.6K
- Shannon Buggy · May 12, 2026 · Tax Withholding9.2K @ $2.75
- Jared Matthew Kenost · May 10, 2026 · Option Exercise5.1K
- Jared Matthew Kenost · May 10, 2026 · Option Exercise7.5K
- Jared Matthew Kenost · May 10, 2026 · Tax Withholding1.9K @ $2.54
- Jared Matthew Kenost · May 10, 2026 · Tax Withholding2.9K @ $2.54
Institutional Ownership
March 31, 2026
- Total shares held
- 50.58M
- Total value held
- $125.81M
- Institutional holders
- 187
- Unknown7.94M
- Unknown7.62M
- Unknown4.22M
- Unknown4.03M
- Unknown2.68M
- Unknown2.17M
- Unknown2.01M
- Unknown1.50M
- Unknown1.35M
- Unknown1.04M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Cronos completes acquisition of CanAdelaar, expands European presence
Cronos Group announced the completion of its acquisition of CanAdelaar, the largest adult‑use cannabis company in Europe. The deal adds a significant European footprint to Cronos’ operations and may enhance its product distribution across the region. Around the same time, Zuanic & Associates initiated coverage of Cronos with an Overweight rating, indicating a favorable view from the analyst. The stock is currently trading near its $2.72 support level with a mid‑range RSI, suggesting modest momentum.
Cronos completes acquisition of CanAdelaar, expands European presence. Cronos Group announced the completion of its acquisition of CanAdelaar, the largest adult‑use cannabis company in Europe. The deal adds a significant European footprint to Cronos’ operations and may enhance its product distribution across the region. Around the same time, Zuanic & Associates initiated coverage of Cronos with an Overweight rating, indicating a favorable view from the analyst. The stock is currently trading near its $2.72 support level with a mid‑range RSI, suggesting modest momentum.